-
Mashup Score: 36European cancer mortality predictions for the year 2024 with focus on colorectal cancer - 2 month(s) ago
We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We focused on mortality from colorectal cancer (CRC).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Chylous effusion is a rare side effect observed during treatment with multikinase inhibitors (MKI) or selective RET tyrosine kinase inhibitors (TKIs) [1]. Pleura (12/22; 54%), peritoneum (5/22; 23%), or both (5/22; 23%) were common sites for chylous effusion. Selpercatinib (15/217; 7%) and MKIs (7/7371; <1%) were the most frequent causes. No confirmed effusion cases were observed with pralsetinib, but two RET rearranged NSCLC patients on pralsetinib had chylous ascites in a recent case series [2].
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET - 2 month(s) ago
18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer - 2 month(s) ago
Immunotherapy has transformed the endometrial cancer treatment landscape , particularly for those exhibiting mismatch repair deficiency (MMRd/MSI-H). A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612), AtTEnd (NCT03603184), and DUO-E (NCT04269200) have been disclosed.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41The co-expression of antigen targets as a rationale for ADCs combination in urothelial cancer - 2 month(s) ago
In a recent issue [1], McGregor et al. reported the first clinical trial testing antibody-drug conjugate (ADC) combination in cancers. They treated 24 patients with refractory metastatic urothelial carcinoma (mUC) with the combination of enfortumab-vedotin (EV) and sacituzumab-govitecan (SG). They observed no new safety signal compared to monotherapy and an impressive 70% objective response rate (ORR). The rationale was absence of overlapping major toxicity of ADCs and in vivo synergy of combining SG with microtubule inhibitors.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10
Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited.The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC - 2 month(s) ago
HER3 is broadly expressed in NSCLC and is the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. U31402-A-U102 is an ongoing phase 1 study of HER3-DXd in patients with advanced NSCLC. Patients with EGFR-mutated NSCLC that progressed after EGFR TKI and platinum-based chemotherapy (PBC) who received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks had a confirmed objective response rate (cORR) of 39%.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC - 2 month(s) ago
HER3 is broadly expressed in NSCLC and is the target of patritumab deruxtecan (HER3-DXd), an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. U31402-A-U102 is an ongoing phase 1 study of HER3-DXd in patients with advanced NSCLC. Patients with EGFR-mutated NSCLC that progressed after EGFR TKI and platinum-based chemotherapy (PBC) who received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks had a confirmed objective response rate (cORR) of 39%.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13ctDNA and radiological tumor volume and risk of relapse with resected, early-stage NSCLC - 2 month(s) ago
Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. In this podcast, Professor John Heymach, University of Texas MD Anderson C
Source: soundcloud.comCategories: General Medicine News, Onc News and JournalsTweet-
The February 2024 issue article of the month⭐️ podcast 🎙️ is now available! Annals of Oncology EiC @tompowles1 interviews Pr. John Heymach from @MDAndersonNews on ctDNA 🩸🧪🧬 in early-stage NSCLC 🫁 Soundcloud: https://t.co/Aywai0tR4W Spotify: https://t.co/dcGrduNK21 #LCSM https://t.co/pbKGHk12xa https://t.co/egyLKCfsvH
-
-
Mashup Score: 15Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 - 3 month(s) ago
KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
"Almost 6.2 million avoided cancer deaths are predicted over 1989-2024 in the EU and 1.3 million in the UK." 🚨 Just out #OpenAccess in Annals of Oncology, the European cancer mortality predictions for the year 2024 with focus on colorectal cancer https://t.co/XqHlE7KvR2